title: Ipilimumab-Associated Retinopathy.
abstract: Ipilimumab is a novel immunotherapeutic agent that improves survival in patients diagnosed with metastatic melanoma. With the rising incidence of melanoma, the use of this pharmacologic agent is increasing. However, ipilimumab can be associated with rare but serious systemic adverse events. While the mechanism of these systemic adverse events is immune-related dysfunction, the index case highlights a possible direct ocular adverse event associated with ipilimumab infusion resulting in bilateral serous retinal detachment. Close observation of ocular findings using multimodal imaging analysis can provide insights into possible pathophysiology of the condition and guide further management.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Crews
authors.forename: Aniruddha
authors.initials: A
authors.lastname: Agarwal
authors.forename: Loren
authors.initials: L
authors.lastname: Jack
authors.forename: Ding
authors.initials: D
authors.lastname: Xu
authors.forename: Diana V
authors.initials: DV
authors.lastname: Do
authors.forename: Quan Dong
authors.initials: QD
authors.lastname: Nguyen
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D005451:Fluorescein Angiography; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects*; D000074324:Ipilimumab; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary; D008875:Middle Aged; D012163:Retinal Detachment / Q000139:chemically induced* / Q000175:diagnosis; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology; D041623:Tomography, Optical Coherence; D014792:Visual Acuity
chemical_list: D000911:Antibodies, Monoclonal; D000074324:Ipilimumab